Taken together, these results show that PRKCSH contributes to the adaptation of tumor cells against TNFSF cytotoxicity by increasing the half-life of IGF1R, which is involved in tumor resistance to antitumor immunity and various cancer therapeutics. The gene discussed is PRKCSH; the disease is neoplasm.